Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Am J Transplant. 2020 Feb 20;20(6):1513–1526. doi: 10.1111/ajt.15777

Figure 7. rhC1INH treatment in BD donors improves graft function and reduces kidney injury and incidence of DGF in transplant recipients.

Figure 7.

(a) Serum creatinine levels in recipients of kidney grafts from donors in G1 (vehicle, n=6), G2 (rhC1INH+ heparin, n=6), and G3 (heparin, n=3). Data are expressed as mean values ±SEM, significance is calculated by two-way ANOVA and Bonferroni’s post-hoc correction (*p<0.05, **p<0.01, G1 vs G2; ††p<0.01, G2 vs G3). (b) Urinary NGAL measured at baseline, day 3, and day 5 post-transplant in recipients of kidney grafts from donors in G1 (vehicle, n=6), G2 (rhC1INH+heparin, n=6), and G3 (heparin, n=3). Data are expressed as mean values ±SEM, significance is calculated by Student’s T-test.